GB0208384D0 - Novel compounds - Google Patents
Novel compoundsInfo
- Publication number
- GB0208384D0 GB0208384D0 GBGB0208384.8A GB0208384A GB0208384D0 GB 0208384 D0 GB0208384 D0 GB 0208384D0 GB 0208384 A GB0208384 A GB 0208384A GB 0208384 D0 GB0208384 D0 GB 0208384D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- novel compounds
- novel
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
- C07C59/215—Saturated compounds having only one carboxyl group and containing keto groups containing singly bound oxygen containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0208384.8A GB0208384D0 (en) | 2002-04-11 | 2002-04-11 | Novel compounds |
| AU2003210234A AU2003210234A1 (en) | 2002-04-11 | 2003-02-10 | Novel thyroid receptor ligands |
| US10/510,645 US20050171104A1 (en) | 2002-04-11 | 2003-02-10 | Novel thyroid receptor ligands |
| PCT/EP2003/001304 WO2003084915A1 (en) | 2002-04-11 | 2003-02-10 | Novel thyroid receptor ligands |
| KR10-2004-7016192A KR20040102080A (ko) | 2002-04-11 | 2003-02-10 | 새로운 갑상선 수용체 리간드 |
| CNB038099373A CN1324001C (zh) | 2002-04-11 | 2003-02-10 | 甲状腺素受体配体 |
| JP2003582114A JP2005522476A (ja) | 2002-04-11 | 2003-02-10 | 新規甲状腺受容体リガンド |
| EP03745755A EP1492756A1 (en) | 2002-04-11 | 2003-02-10 | Novel thyroid receptor ligands |
| CA002481976A CA2481976A1 (en) | 2002-04-11 | 2003-02-10 | Novel thyroid receptor ligands |
| IL16440604A IL164406A0 (en) | 2002-04-11 | 2004-02-10 | Phenoxy indane derivetives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0208384.8A GB0208384D0 (en) | 2002-04-11 | 2002-04-11 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB0208384D0 true GB0208384D0 (en) | 2002-05-22 |
Family
ID=9934685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB0208384.8A Ceased GB0208384D0 (en) | 2002-04-11 | 2002-04-11 | Novel compounds |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20050171104A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1492756A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005522476A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20040102080A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1324001C (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003210234A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2481976A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB0208384D0 (cg-RX-API-DMAC7.html) |
| IL (1) | IL164406A0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003084915A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8501223B2 (en) | 2003-06-20 | 2013-08-06 | Hill's Pet Nutrition, Inc. | Methods for dietary management of cats to avoid hyperthyroidism |
| EP2428516A1 (en) | 2003-11-19 | 2012-03-14 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| EP1849465A4 (en) * | 2005-02-18 | 2008-12-24 | Takeda Pharmaceutical | AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR |
| US20090232879A1 (en) | 2005-05-26 | 2009-09-17 | Metabasis Therapeutics, Inc. | Thyromimetics for the Treatment of Fatty Liver Diseases |
| JP5356831B2 (ja) * | 2006-01-26 | 2013-12-04 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | ネコ科動物の甲状腺機能亢進症を治療するための方法及び組成物 |
| CA2656608C (en) * | 2006-07-03 | 2014-09-16 | Hill's Pet Nutrition, Inc. | Compositions and methods for preventing or treating cardiovascular diseases in felines with hyperthyroidism |
| JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−2,4−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
| AU2007314405A1 (en) * | 2006-10-31 | 2008-05-08 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| KR101396606B1 (ko) | 2009-04-20 | 2014-05-16 | 미쓰비시 타나베 파마 코퍼레이션 | 신규 갑상선 호르몬 β 수용체 작동약 |
| SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| CN105237381A (zh) * | 2015-10-14 | 2016-01-13 | 湖南华腾制药有限公司 | 5-羟基-1-茚酮的制备方法 |
| CN105330525A (zh) * | 2015-10-25 | 2016-02-17 | 湖南华腾制药有限公司 | 7-羟基-1-茚酮的制备方法 |
| WO2018094265A2 (en) | 2016-11-21 | 2018-05-24 | Viking Therapeutics, Inc. | Method of treating glycogen storage disease |
| AU2018280118B2 (en) | 2017-06-05 | 2021-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| EP3683306A4 (en) | 2017-09-14 | 2021-06-09 | Riken | METHOD FOR MANUFACTURING RETINAGE TISSUE |
| CN107929273A (zh) * | 2017-12-01 | 2018-04-20 | 崔坤元 | 肝脏靶向药物 |
| EA202091979A1 (ru) | 2018-03-22 | 2021-06-22 | Вайкинг Терапьютикс, Инк. | Кристаллические формы и способы получения кристаллических форм соединения |
| EP4775207A2 (en) | 2018-12-05 | 2026-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| SG11202109855PA (en) | 2019-03-13 | 2021-10-28 | Sumitomo Dainippon Pharma Co Ltd | Method for evaluating quality of transplant neural retina, and transplant neural retina sheet |
| EP4161925A4 (en) | 2020-06-09 | 2024-09-04 | Viking Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES |
| EP4201428A4 (en) | 2020-09-11 | 2024-09-11 | Sumitomo Pharma Co., Ltd. | MEDIUM FOR TISSUE INTENDED FOR TRANSPLANTATION |
| JPWO2022054925A1 (cg-RX-API-DMAC7.html) | 2020-09-11 | 2022-03-17 | ||
| KR20240103018A (ko) | 2021-11-19 | 2024-07-03 | 고쿠리쓰 겐큐 가이하쓰 호징 리가가쿠 겐큐소 | 시트상 망막 조직의 제조 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9713739D0 (en) * | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
| GB9828442D0 (en) * | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
| GB9927056D0 (en) * | 1999-11-17 | 2000-01-12 | Karobio Ab | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
| PL201790B1 (pl) * | 2000-02-17 | 2009-05-29 | Bristol Myers Squibb Co | Anilinopochodny ligand dla receptora tarczycy, jego zastosowanie i kompozycja farmaceutyczna |
| GB0015205D0 (en) * | 2000-06-21 | 2000-08-09 | Karobio Ab | Bioisosteric thyroid receptor ligands and method |
| GB0111861D0 (en) * | 2001-05-15 | 2001-07-04 | Karobio Ab | Novel compounds |
-
2002
- 2002-04-11 GB GBGB0208384.8A patent/GB0208384D0/en not_active Ceased
-
2003
- 2003-02-10 US US10/510,645 patent/US20050171104A1/en not_active Abandoned
- 2003-02-10 KR KR10-2004-7016192A patent/KR20040102080A/ko not_active Withdrawn
- 2003-02-10 WO PCT/EP2003/001304 patent/WO2003084915A1/en not_active Ceased
- 2003-02-10 JP JP2003582114A patent/JP2005522476A/ja active Pending
- 2003-02-10 CN CNB038099373A patent/CN1324001C/zh not_active Expired - Fee Related
- 2003-02-10 EP EP03745755A patent/EP1492756A1/en not_active Withdrawn
- 2003-02-10 AU AU2003210234A patent/AU2003210234A1/en not_active Abandoned
- 2003-02-10 CA CA002481976A patent/CA2481976A1/en not_active Abandoned
-
2004
- 2004-02-10 IL IL16440604A patent/IL164406A0/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040102080A (ko) | 2004-12-03 |
| US20050171104A1 (en) | 2005-08-04 |
| CN1324001C (zh) | 2007-07-04 |
| CA2481976A1 (en) | 2003-10-16 |
| AU2003210234A1 (en) | 2003-10-20 |
| WO2003084915A1 (en) | 2003-10-16 |
| CN1649819A (zh) | 2005-08-03 |
| JP2005522476A (ja) | 2005-07-28 |
| EP1492756A1 (en) | 2005-01-05 |
| IL164406A0 (en) | 2005-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0202216D0 (en) | Novel compounds | |
| GB0205256D0 (en) | Novel compounds | |
| GB0202679D0 (en) | Novel compounds | |
| GB0206723D0 (en) | Novel compounds | |
| GB0207249D0 (en) | Novel compounds | |
| GB0207246D0 (en) | Novel compounds | |
| GB0203299D0 (en) | Novel compounds | |
| GB0200025D0 (en) | Novel compounds | |
| GB0204252D0 (en) | Novel compounds | |
| GB0206714D0 (en) | Novel compounds | |
| GB0206201D0 (en) | Novel compounds | |
| GB0201357D0 (en) | Novel compounds | |
| GB0207282D0 (en) | Novel compounds | |
| GB0205649D0 (en) | Novel compounds | |
| GB0206716D0 (en) | Novel compounds | |
| GB0201231D0 (en) | Novel compounds | |
| GB0202636D0 (en) | Novel compounds | |
| GB0203901D0 (en) | Novel compounds | |
| GB0206196D0 (en) | Novel compounds | |
| GB0207278D0 (en) | Novel compounds | |
| GB0203437D0 (en) | Novel compounds | |
| GB0204758D0 (en) | Novel compounds | |
| GB0203300D0 (en) | Novel compounds | |
| GB0202442D0 (en) | Novel compounds | |
| GB0202141D0 (en) | Novel compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |